scholarly journals Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

2013 ◽  
Vol 19 (4) ◽  
pp. 809-820 ◽  
Author(s):  
Tarrik M. Zaid ◽  
Tsz-Lun Yeung ◽  
Melissa S. Thompson ◽  
Cecilia S. Leung ◽  
Tom Harding ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Therapeutic Target ◽  
High Grade ◽  
Advanced Stage ◽  
Serous Ovarian Cancer ◽  
Potential Therapeutic Target

Cyclin E as a potential therapeutic target in high grade serous ovarian cancer

2016 ◽  
Vol 143 (1) ◽  
pp. 152-158 ◽  
Author(s):  
J. Kanska ◽  
M. Zakhour ◽  
B. Taylor-Harding ◽  
B.Y. Karlan ◽  
W.R. Wiedemeyer
Keyword(s):  
Ovarian Cancer ◽  
Therapeutic Target ◽  
Cyclin E ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Potential Therapeutic Target

scholarly journals Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer

2021 ◽  
Vol 2 (12) ◽  
pp. 100471
Author(s):  
Dongqing Huang ◽  
Shrabanti Chowdhury ◽  
Hong Wang ◽  
Sara R. Savage ◽  
Richard G. Ivey ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Therapeutic Target ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Potential Therapeutic Target ◽  
Platinum Refractory

Neurotensin signaling pathway as a potential therapeutic target in high-grade serous ovarian cancer

2018 ◽  
Vol 149 ◽  
pp. 71
Author(s):  
E.J. Norris ◽  
D. DeStephanis ◽  
Q. Zhang ◽  
D.L. Tait ◽  
R. Ganapathi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Signaling Pathway ◽  
Therapeutic Target ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Potential Therapeutic Target

scholarly journals SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery

2020 ◽  
Vol 7 (6) ◽  
pp. 1805094
Author(s):  
Maria Bååth ◽  
Sofia Westbom-Fremer ◽  
Laura Martin de la Fuente ◽  
Anna Ebbesson ◽  
Juliette Davis ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Residual Disease ◽  
High Grade ◽  
Advanced Stage ◽  
Serous Ovarian Cancer ◽  
Debulking Surgery

scholarly journals KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer

2020 ◽  
Vol 39 (1) ◽  
Author(s):  
Marta De Donato ◽  
Gabriele Babini ◽  
Simona Mozzetti ◽  
Marianna Buttarelli ◽  
Alessandra Ciucci ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Overall Survival ◽  
Prognostic Marker ◽  
Late Stage ◽  
Therapeutic Target ◽  
Family Members ◽  
High Grade ◽  
Serous Ovarian Cancer

Abstract Background In spite of great progress in the surgical and clinical management, until now no significant improvement in overall survival of High-Grade Serous Ovarian Cancer (HGSOC) patients has been achieved. Important aspects for disease control remain unresolved, including unclear pathogenesis, high heterogeneity and relapse resistance after chemotherapy. Therefore, further research on molecular mechanisms involved in cancer progression are needed to find new targets for disease management. The Krüppel-like factors (KLFs) are a family of transcriptional regulators controlling several basic cellular processes, including proliferation, differentiation and migration. They have been shown to play a role in various cancer-relevant processes, in a context-dependent way. Methods To investigate a possible role of KLF family members as prognostic biomarkers, we carried out a bioinformatic meta-analysis of ovarian transcriptome datasets in different cohorts of late-stage HGSOC patients. In vitro cellular models of HGSOC were used for functional studies exploring the role of KLF7 in disease development and progression. Finally, molecular modelling and virtual screening were performed to identify putative KLF7 inhibitors. Results Bioinformatic analysis highlighted KLF7 as the most significant prognostic gene, among the 17 family members. Univariate and multivariate analyses identified KLF7 as an unfavourable prognostic marker for overall survival in late-stage TCGA-OV and GSE26712 HGSOC cohorts. Functional in vitro studies demonstrated that KLF7 can play a role as oncogene, driving tumour growth and dissemination. Mechanistic targets of KLF7 included genes involved in epithelial to mesenchymal transition, and in maintaining pluripotency and self-renewal characteristics of cancer stem cells. Finally, in silico analysis provided reliable information for drug-target interaction prediction. Conclusions Results from the present study provide the first evidence for an oncogenic role of KLF7 in HGSOC, suggesting it as a promising prognostic marker and therapeutic target.

scholarly journals Molecular Profiling and Clinical Outcome of High-Grade Serous Ovarian Cancer Presenting with Low- versus High-Volume Ascites

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Tomer Feigenberg ◽  
Blaise Clarke ◽  
Carl Virtanen ◽  
Anna Plotkin ◽  
Michelle Letarte ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Immune Response ◽  
Clinical Outcome ◽  
Expression Profiles ◽  
High Volume ◽  
High Grade ◽  
Advanced Stage ◽  
Serous Ovarian Cancer ◽  
Immune Response Genes ◽  
Low Volume

Epithelial ovarian cancer consists of multiple histotypes differing in etiology and clinical course. The most prevalent histotype is high-grade serous ovarian cancer (HGSOC), which often presents at an advanced stage frequently accompanied with high-volume ascites. While some studies suggest that ascites is associated with poor clinical outcome, most reports have not differentiated between histological subtypes or tumor grade. We compared genome-wide gene expression profiles from a discovery cohort of ten patients diagnosed with stages III-IV HGSOC with high-volume ascites and nine patients with low-volume ascites. An upregulation of immune response genes was detected in tumors from patients presenting with low-volume ascites relative to those with high-volume ascites. Immunohistochemical studies performed on tissue microarrays confirmed higher expression of proteins encoded by immune response genes and increased tumorinfiltrating cells in tumors associated with low-volume ascites. Comparison of 149 advanced-stage HGSOC cases with differential ascites volume at time of primary surgery indicated low-volume ascites correlated with better surgical outcome and longer overall survival. These findings suggest that advanced stage HGSOC presenting with low-volume ascites reflects a unique subgroup of HGSOC, which is associated with upregulation of immune related genes, more abundant tumor infiltrating cells and better clinical outcomes.

scholarly journals Notch3 Overexpression as Potential Therapeutic Target in Advanced Stage Chemoresistant Ovarian Cancer

2012 ◽  
Vol 138 (4) ◽  
pp. 535-544 ◽  
Author(s):  
Mohammed Tanjimur Rahman ◽  
Kentaro Nakayama ◽  
Munmun Rahman ◽  
Hiroshi Katagiri ◽  
Atsuko Katagiri ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Therapeutic Target ◽  
Advanced Stage ◽  
Potential Therapeutic Target ◽  
Chemoresistant Ovarian Cancer

EP777 Survival of advanced stage high grade serous ovarian cancer patients in republic of north macedonia

2019 ◽  
Author(s):  
I Aluloski ◽  
M Tanturovski ◽  
S Kostadinova-Kunovska ◽  
R Jovanovic ◽  
G Petrusevska
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
High Grade ◽  
Advanced Stage ◽  
Serous Ovarian Cancer
Sign in / Sign up

Export Citation Format

Share Document